NCT04045028: Phase 1: Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04045028: Phase 1: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

This is a Phase I open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of tiragolumab administered as a single agent or in combination with atezolizumab and/or daratumumab or rituximab in participants with relapsed or refractory (R/R) multiple myeloma (MM) or R/R non-Hodgkin lymphoma (NHL).

Sponsor

Genentech, Inc.

Multiple Locations

International Study

---

ClinicalTrials.gov Identifier: NCT04045028

Official Title: A Phase Ia/Ib Open-Label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma, and as a Single Agent and in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

First Posted : August 5, 2019

Click here to see details on ClinicalTrials.gov

---

Drug: Tiragolumab

Drug: Daratumumab/rHuPH20

Drug: Rituximab

Drug: Atezolizumab

---

Tiragolumab

Tiragolumab (Code C131291)

MTIG7192A

RG6058

Tiragolumab

TIRAGOLUMAB

---

Locations

United States, Colorado

United States, Georgia

United States, Maryland

United States, Missouri

United States, Ohio

United States, Pennsylvania

United States, Tennessee

United States, Virginia

Asia

Korea, Republic of